Momenta Pharmaceuticals (NASDAQ:MNTA) is set to release its earnings data before the market opens on Wednesday, November 7th. Analysts expect Momenta Pharmaceuticals to post earnings of ($0.62) per share for the quarter.
Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.91) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.50). The company had revenue of $13.00 million during the quarter, compared to analyst estimates of $15.83 million. Momenta Pharmaceuticals had a negative net margin of 128.49% and a negative return on equity of 40.55%. The firm’s revenue for the quarter was down 44.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.50) EPS. On average, analysts expect Momenta Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
MNTA traded up $0.66 during midday trading on Thursday, reaching $13.17. 13,181 shares of the company’s stock were exchanged, compared to its average volume of 1,038,882. The stock has a market cap of $988.33 million, a P/E ratio of -10.83 and a beta of 1.75. Momenta Pharmaceuticals has a 1-year low of $11.72 and a 1-year high of $32.20.
In other Momenta Pharmaceuticals news, CEO Craig A. Wheeler sold 1,773 shares of Momenta Pharmaceuticals stock in a transaction dated Friday, August 10th. The shares were sold at an average price of $26.06, for a total transaction of $46,204.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Elizabeth Stoner sold 4,152 shares of Momenta Pharmaceuticals stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $27.33, for a total transaction of $113,474.16. Following the transaction, the director now owns 33,791 shares of the company’s stock, valued at approximately $923,508.03. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,589 shares of company stock valued at $345,785. 4.80% of the stock is currently owned by company insiders.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.
Featured Story: Ex-Dividend
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.